Non-Small-Cell Lung Cancer | Treatment Sequencing | US | 2019
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who the competition is and how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
- Where is my product positioned versus competitors’ products in the treatment journey?
- What are physicians’ most frequent treatment sequences—who is benefiting and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the patient journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. medical oncologists
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
